BDTX

Business Context and Reporting Period

Company: Black Diamond Therapeutics, Inc. (BDTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A clinical-stage oncology company developing "MasterKey" therapies targeting oncogenic mutations. The lead asset is silevertinib, a brain-penetrant EGFR inhibitor for non-small cell lung cancer (NSCLC) and glioblastoma (GBM). The company outlicensed its second asset, BDTX-4933, to Servier Pharmaceuticals in March 2025.

Key Financial Metrics

Liquidity: As of June 30, 2026, the company held $19.2 million in cash and cash equivalents and $91.3 million in investments. Management expects these resources to fund operations into the second half of 2028.

Material Changes vs. Prior Period

• Revenue: Revenue dropped to $0 from $70.0 million in the prior year period. The 2025 revenue was driven by a one-time $70.0 million upfront payment from the Servier licensing agreement for BDTX-4933, which was recognized in Q1 2025.
• Operating Expenses: Total operating expenses decreased by $5.6 million (19%) to $23.3 million.
  • R&D Expenses: Decreased by $5.4 million to $14.4 million. This reduction was primarily due to the deprioritization of the BDTX-4933 program (now Servier's responsibility) and lower spend on the silevertinib NSCLC Phase 2 trial. This was partially offset by $4.0 million in new costs for the initiation of the silevertinib GBM Phase 2 trial.
  • G&A Expenses: Decreased slightly by $0.1 million to $8.9 million due to operational efficiencies.
• Net Income/Loss: The company reported a net loss of $18.9 million compared to net income of $46.0 million in the prior year, reflecting the absence of the Servier upfront payment.

Outlook, Risks, and Management Commentary

• Clinical Progress:
  • Silevertinib (NSCLC): Final Phase 2 data presented at ASCO 2026 showed encouraging responses in 83 patients. Frontline data (43 patients) showed a median progression-free survival (mPFS) of 15.2 months and a CNS objective response rate of 86%.
  • Silevertinib (GBM): Initiated a randomized Phase 2 trial in newly diagnosed EGFRvIII+ glioblastoma patients in May 2026. The trial expects to enroll ~150 patients with an interim analysis anticipated in H1 2028.
• Partnerships: The company is evaluating strategic alternatives and partnership opportunities to advance silevertinib into pivotal development. The Servier agreement for BDTX-4933 remains active, with potential for up to $710 million in milestones and tiered royalties.
• Funding Needs: The company expects expenses to increase substantially as it advances clinical trials. It anticipates needing additional capital beyond the second half of 2028. Funding sources may include equity offerings (including an active ATM program), debt, or collaborations.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to secure additional financing on acceptable terms, and the potential for delays in regulatory approvals. The company is also monitoring macroeconomic and geopolitical factors.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the management estimate that current liquidity ($110.5 million) will sustain operations into the second half of 2028, given the burn rate of ~$18.2 million per six months.
• GBM Trial Enrollment: Monitor the enrollment progress and safety data of the newly initiated Phase 2 GBM trial, which is critical for the asset's value proposition.
• Partnership Status: Track any announcements regarding strategic partnerships for silevertinib, as the company has indicated it is evaluating options for pivotal development.
• ATM Program Activity: Review future filings for sales under the At-The-Market (ATM) program, which has generated $25.0 million in gross proceeds to date, to assess dilution impact.
• Servier Milestones: Monitor Servier's progress with BDTX-4933, as future revenue is contingent on development and commercial milestones that are currently uncertain.